MariMed Inc. (MRMD) director receives, converts 192,308 RSUs

(Neutral)

Form Type

Rhea-AI Filing Summary

MariMed Inc. director Edward J. Gildea received 192,308 restricted stock units on July 15, 2026 as part of his board fees, granted in lieu of cash. These RSUs vested immediately and converted one-for-one into 192,308 common shares at no cash cost, increasing his direct holdings to 1,172,516 shares and leaving no RSUs outstanding from this award.

Insider Trade Summary

Net Buyer: 192,308 shares

Net Buy 3 txns

Insider Gildea Edward J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSU) ^{F1, F2}	192,308	$0.00	$0.00
Exercise	Restricted Stock Units (RSU) ^{F1, F2}	192,308	$0.00	$0.00
Exercise	Common stock ^F1	192,308	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (RSU) — 0 shares (Direct); Common stock — 1,172,516 shares (Direct)

Footnotes (2)

F1. RSUs convert to shares of common stock on a one-for-one basis.
F2. The RSUs were granted on July 15, 2026 and vested upon grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Accordingly, no RSUs remain outstanding under this award.

Key Figures

RSUs granted: 192,308 units Common shares received from RSU conversion: 192,308 shares Common shares held after transaction: 1,172,516 shares +2 more

5 metrics

RSUs granted 192,308 units Restricted Stock Units granted to director on July 15, 2026

Common shares received from RSU conversion 192,308 shares Common stock issued upon one-for-one RSU conversion

Common shares held after transaction 1,172,516 shares Director’s direct MariMed common stock holdings following Form 4 transactions

Transaction price per share 0.0000 per share Reported per-share price for RSU-to-common stock conversion

Derivative exercises reported 1 transaction; 192,308 shares Exercise or conversion of derivative security on July 15, 2026

Key Terms

Restricted Stock Units (RSU), vested upon grant, in lieu of cash, one-for-one basis

4 terms

Restricted Stock Units (RSU) financial

"security_title: Restricted Stock Units (RSU)"

vested upon grant financial

"The RSUs were granted on July 15, 2026 and vested upon grant"

in lieu of cash financial

"RSUs were granted in lieu of cash as payment for a portion of fees"

one-for-one basis financial

"RSUs convert to shares of common stock on a one-for-one basis"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 04:10 PM Accepted by SEC EDGAR 07/17/2026 - 04:10 PM

FAQ

What insider transactions did MRMD director Edward J. Gildea report on this Form 4?

Edward J. Gildea reported receiving 192,308 restricted stock units that immediately vested and were converted into 192,308 common shares. The award was compensation for serving on MariMed’s board, taken in equity rather than cash, and increased his directly held common stock position.

How many MRMD shares and RSUs were involved in Edward J. Gildea’s July 15, 2026 transactions?

The filing shows 192,308 restricted stock units granted and a corresponding conversion into 192,308 common shares. Footnotes state the RSUs convert to common stock on a one-for-one basis and that none from this particular award remain outstanding after the same-day vesting and conversion.

Why did MariMed (MRMD) grant RSUs to Edward J. Gildea instead of paying cash?

MariMed states the RSUs were granted in lieu of cash as payment for a portion of Edward J. Gildea’s board fees. This means part of his compensation for serving on the board was settled in equity rather than cash, aligning his compensation with company stock.

What is Edward J. Gildea’s MariMed (MRMD) common stock holding after these transactions?

After the July 15, 2026 conversion, Edward J. Gildea directly holds 1,172,516 shares of MariMed common stock. This figure reflects the addition of 192,308 shares received from the vested restricted stock units and is reported as his total direct common stock ownership following the transaction.

Do any restricted stock units from this MRMD award remain outstanding for Edward J. Gildea?

No RSUs from this award remain outstanding. A footnote explains the 192,308 RSUs granted on July 15, 2026 vested upon grant and were converted into common stock, and it specifically states that no restricted stock units remain outstanding under this particular award.

Were Edward J. Gildea’s MRMD equity transactions made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote referencing a trading plan. This suggests the reported grant, vesting, and conversion of restricted stock units were not executed under a pre-arranged Rule 10b5-1 trading arrangement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gildea Edward J

(Last)

(First)

(Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD

MASSACHUSETTS

02062

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	07/15/2026		M		192,308	A	$0⁽¹⁾	1,172,516	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units (RSU)	⁽¹⁾	07/15/2026		A		192,308		⁽²⁾	⁽²⁾	Common Stock, par value $.001 per share	192,308	$0	192,308	D
Restricted Stock Units (RSU)	⁽¹⁾	07/15/2026		M			192,308	⁽²⁾	⁽²⁾	Common Stock, par value $.001 per share	192,308	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs were granted on July 15, 2026 and vested upon grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Accordingly, no RSUs remain outstanding under this award.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ Edward Gildea	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR